Mika Scheinin
MD, PhD, Professor Emeritus
Bioanalytics; Clinical Pharmacology; Drug Development; Positron Emission Tomography; Research Ethics
- Safety and Immunogenicity of a Vaccine Against Coxsackieviruses B (PRV-101)-Follow-up of the First-in-Human Phase 1 Trial (2026)
- Open Forum Infectious Diseases
- Safety, tolerability and immunogenicity of vaccine ALZ-101 in patients with early Alzheimer’s disease: randomised, controlled trial (2026)
- Alzheimer's Research and Therapy
- Stability of oxycodone solutions containing S-ketamine or dexmedetomidine (2026)
- European Journal of Hospital Pharmacy: Science and Practice
- Combined Immediate‐Release and Extended‐Release Formulation of Sodium Valproate Provides Stable Plasma Levels for Inhibition of Histone Deacetylation (2025)
- Clinical Pharmacology in Drug Development
- Effects of Dietary Restriction on Regulation of Energy Metabolism in Male Wistar Rats (Rattus norvegicus) (2025)
- Jaalas
- Vasomotion in Human Fingers (2025)
- Journal of Vascular Research
- Adrenoseptoreihin vaikuttavat lääkeaineet (2024) Lääketieteellinen farmakologia ja toksikologia Salminen, Outi; Scheinin, Mika
- Adrenoseptoriagonistien farmakologiaa (2024) Lääketieteellinen farmakologia ja toksikologia Salminen, Outi; Scheinin, Mika
- Adrenoseptoriantagonistit (2024) Lääketieteellinen farmakologia ja toksikologia Salminen, Outi; Scheinin, Mika
- Adrenoseptorien välittämät vaikutukset (2024) Lääketieteellinen farmakologia ja toksikologia Salminen, Outi; Scheinin, Mika



